Today they represent 15% of the world drug Job Function Email List market, more than 600,000 million dollars, and it is expected that they will reach 25% in the next ten years, especially due to the expiration of patents. In 2009 Sigman created mAbxience, a division of Chemo Job Function Email List specializing in monoclonal antibodies, or mAbs, biosimilars used to neutralize foreign objects such as tumors. In 2012 he inaugurated the pilot plant in Munro, an old semi-abandoned Job Function Email List industrial hub in the north of the province of Buenos Aires. The company soon made agreements with laboratories in Russia, Iran, Turkey, and Southeast Asia. Sigman's biotechnological adventures in.
America know two milestones. The first is the Job Function Email List development of a vaccine to treat lung cancer. A project that Sigman began in the mid-1990s in Cuba, with the development of the NgcCM3 antigen, and culminated in 2013 with the presentation of Racotumomab , the first vaccine that makes lung cancer chronic, transforming a deadly disease Job Function Email List into a treatable disease such as diabetes or hypertension. The 18 years of research and development involved Sigman's companies, national universities, Cuban and Argentine research centers (including the National Council for Scientific and Technical Research of Argentina) and the support of two ministries. The second milestone was the Job Function Email List creation of Sinergium Biotech. During the 2009 H1N1 flu pandemic.
Sigman proposed to the Argentine government, through Job Function Email List the then Minister of Health Juan Manzur, a pharmaceutical technology transfer project in exchange for the granting of a provisional monopoly, inspired by a similar project of the Brazilian Job Function Email List government. The tender was presented favoring Sigman as "author of the initiative", with the commitment to acquire all the vaccines produced. The agreement was made with the multinational Novartis, which would have a three-year monopoly on the flu vaccine, while transferring the technology to Elea and Job Function Email List Biogenesis Bagó, through a company created for this purpose: Sinergium Biotech. After three years, Sinergium would be the exclusive manufacturer. In 2012, the World.